HUP0202515A2 - Mezoprogesztogének (progeszteron receptor modulátorok) alkalmazása női fogamzásgátló gyógyszer komponenseként - Google Patents

Mezoprogesztogének (progeszteron receptor modulátorok) alkalmazása női fogamzásgátló gyógyszer komponenseként

Info

Publication number
HUP0202515A2
HUP0202515A2 HU0202515A HUP0202515A HUP0202515A2 HU P0202515 A2 HUP0202515 A2 HU P0202515A2 HU 0202515 A HU0202515 A HU 0202515A HU P0202515 A HUP0202515 A HU P0202515A HU P0202515 A2 HUP0202515 A2 HU P0202515A2
Authority
HU
Hungary
Prior art keywords
progesterone receptor
mesoprogestins
component
female
receptor modulators
Prior art date
Application number
HU0202515A
Other languages
English (en)
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Jenapharm Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg
Publication of HUP0202515A2 publication Critical patent/HUP0202515A2/hu
Publication of HUP0202515A3 publication Critical patent/HUP0202515A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Abstract

A találmány tárgya mezoprogesztogének alkalmazása női fogamzásgátlógyógyszerek előállítására, női fogamzásgátlásra alkalmasgyógyszerkészítmények, és eljárás női fogamzásgátlásra, amelynek soránvalamely mezoprogesztogén hatékony mennyiségét adagolják a fogamzásellen védekezni kívánó nőnek. Adott esetben a mezoprogesztogénösztrogénnel kombinálható. A mezoprogesztogének olyan vegyületkéntdefiniálhatók, amelyek a progeszteron receptorra (PR) in vivo agonistaés antagonista hatást egyaránt kifejtenek. Ó
HU0202515A 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives HUP0202515A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31
PCT/IB2000/002053 WO2001026603A2 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Publications (2)

Publication Number Publication Date
HUP0202515A2 true HUP0202515A2 (hu) 2002-12-28
HUP0202515A3 HUP0202515A3 (en) 2004-06-28

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202515A HUP0202515A3 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Country Status (28)

Country Link
EP (1) EP1605949A2 (hu)
JP (1) JP2003511399A (hu)
KR (1) KR20020038745A (hu)
CN (1) CN1384748A (hu)
AR (1) AR025455A1 (hu)
AU (1) AU781835B2 (hu)
BG (1) BG106441A (hu)
BR (1) BR0013711A (hu)
CA (1) CA2383650A1 (hu)
CO (1) CO5190694A1 (hu)
CZ (1) CZ2002707A3 (hu)
EA (1) EA006805B1 (hu)
EE (1) EE200200103A (hu)
HR (1) HRP20020265A2 (hu)
HU (1) HUP0202515A3 (hu)
IL (1) IL148415A0 (hu)
LT (1) LT5001B (hu)
LV (1) LV12940B (hu)
MX (1) MXPA02002186A (hu)
NO (1) NO20020998L (hu)
NZ (1) NZ517470A (hu)
PE (1) PE20010579A1 (hu)
PL (1) PL353994A1 (hu)
SI (1) SI20853A (hu)
SK (1) SK2982002A3 (hu)
UA (1) UA77150C2 (hu)
WO (1) WO2001026603A2 (hu)
YU (1) YU13902A (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
DE50304970D1 (de) * 2002-08-02 2006-10-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
EP1624848A4 (en) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
TW200603813A (en) * 2004-07-07 2006-02-01 Wyeth Corp Cyclic progestin regimens and kits
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
US9616073B2 (en) * 2009-04-14 2017-04-11 Laboratoire Hra-Pharma Method for on-demand contraception
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
NZ226316A (en) * 1987-09-24 1991-10-25 Jencap Research Ltd Pharmaceutical contraceptive preparations and packages containing from 20-35 unit dosages comprising an estrogen and a progestin; the unit dosages having alternating estrogen and progestin dominance
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4429398C2 (de) 1994-08-09 1997-09-11 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0787002B1 (de) * 1994-10-24 2006-12-13 Schering Aktiengesellschaft Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
PL330916A1 (en) * 1996-06-25 1999-06-07 Akzo Nobel Nv Progestagen-antiprogestagen dosing schemes
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
CN1353717A (zh) * 1999-05-04 2002-06-12 莱加制药公司 四环黄体酮受体调节剂化合物及其方法

Also Published As

Publication number Publication date
BG106441A (bg) 2002-09-30
EP1605949A2 (en) 2005-12-21
HUP0202515A3 (en) 2004-06-28
AR025455A1 (es) 2002-11-27
CZ2002707A3 (cs) 2002-11-13
LV12940B (en) 2003-06-20
WO2001026603A3 (en) 2002-01-17
WO2001026603A2 (en) 2001-04-19
KR20020038745A (ko) 2002-05-23
MXPA02002186A (es) 2002-09-02
SK2982002A3 (en) 2002-07-02
SI20853A (sl) 2002-10-31
LT2002035A (lt) 2002-10-25
AU3215001A (en) 2001-04-23
PE20010579A1 (es) 2001-06-04
CA2383650A1 (en) 2001-04-19
YU13902A (sh) 2006-01-16
IL148415A0 (en) 2002-09-12
AU781835B2 (en) 2005-06-16
NO20020998D0 (no) 2002-02-28
EE200200103A (et) 2003-04-15
HRP20020265A2 (en) 2004-02-29
NO20020998L (no) 2002-03-14
LT5001B (lt) 2003-03-25
JP2003511399A (ja) 2003-03-25
PL353994A1 (en) 2003-12-15
BR0013711A (pt) 2002-05-07
UA77150C2 (en) 2006-11-15
CN1384748A (zh) 2002-12-11
EA006805B1 (ru) 2006-04-28
CO5190694A1 (es) 2002-08-29
EA200200284A1 (ru) 2002-10-31
NZ517470A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
HK1109586A1 (en) Slow release estradiol-progesterone formulation
HUP0101543A2 (hu) Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények
HUP0204349A2 (en) Novel topical oestroprogestational compositions with systemic effect
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
PT87053A (pt) Processo para a preparacao de composicoes contraceptivas contendo meletonina e metodo para efectuar a contracepcao
HUP0303182A2 (hu) Gyógyászati készítmények
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
HUP0402651A2 (hu) Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények és egységcsomagok
HUP0202515A2 (hu) Mezoprogesztogének (progeszteron receptor modulátorok) alkalmazása női fogamzásgátló gyógyszer komponenseként
HUP9900612A2 (hu) Új hormonális gyógyászati készítmények, valamint a készítmények alkalmazása ösztrogénpótlásra
HUP9904508A2 (hu) Egy ösztrogén vegyületet és egy progesztatív vegyületet tartalmazó hormonkészítmény
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
AU9028098A (en) Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
YU14002A (sh) Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja
WO2004011029A3 (en) Pharmaceutical compositions for penis enlargement
Csapo et al. Menstrual induction in preference to abortion
HUP0202460A2 (hu) A mezoprogesztinek (progeszteron-receptor-modulátorok), mint hormonpótlásos kezelésre alkalmas készítmények komponensei
Ulla NUVARING-ACCEPTABILITY OF WOMEN AND PARTNER
Lello et al. Clinical trial of a monophasic estroprogestin oral formulation containing 20 μg ethinyl estradiol and 75 μg gestodene
Moggia et al. Evaluation of the contraceptive efficacy of quingestanol acetate (W 4540) when administered as an oral low-dose conraceptive in the puerperium
WO2000078298A3 (en) Programming ovulation by administering estrogen such as estradiol
Dumont et al. Contraception in teenage girls: practical aspects
Huffman Oral Contraceptives vs. a weekly contraceptive patch
WO2002053168A3 (fr) La pilule sterilisante